| Literature DB >> 30034945 |
Xiaowen Tang1,2, Lin Yang2,3,4, Zheng Li5,1,2, Ansel P Nalin6, Haiping Dai5,1,2, Ting Xu5,1,2, Jia Yin5,1,2, Fengtao You2,3,4, Mingqing Zhu5,1,2, Wenhong Shen5,1,2, Guanghua Chen5,1,2, Xiaming Zhu5,1,2, Depei Wu5,1,2, Jianhua Yu6,7,8.
Abstract
CAR T cells have shown clinical efficacy for acute lymphoblastic leukemia, but this therapy has not been effective for acute myeloid leukemia (AML), and other treatment options are needed. Theoretically, CAR-NK cells have a more favorable toxicity profile compared to CAR T cells, especially in avoiding adverse effects such as cytokine release syndrome. However, the clinical evidence for this has not yet been reported. In the current study, we tested the safety of CD33-CAR NK cells in patients with relapsed and refractory AML. At doses up to 5 × 109 (5 billion) cells per patient, no significant adverse effects were observed. CAR NK-92 cells can be produced at much lower cost compared to CAR T cells, and we believe after being optimized, they will be widely accessible for the treatment of cancer.Entities:
Keywords: CAR NK-92 cells; CD33; acute myeloid leukemia; refractory; relapsed; safety test
Year: 2018 PMID： 30034945 PMCID： PMC6048396
Source DB: PubMed Journal: Am J Cancer Res ISSN： 2156-6976 Impact factor: 6.166